Hyponatremia in cancer patients: time for a new approach

Highlights • Hyponatremia is relevant in cancer patients because it may have a negative impact on outcome, on quality of life and on length of hospitalization. • There are evidences that the inappropriate antidiuretic hormone syndrome (SIADH) is the most common cause of hyponatremia in cancer patien...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncology/hematology Vol. 102; pp. 15 - 25
Main Authors Rossana, Berardi, Silvia, Rinaldi, Miriam, Caramanti, Christian, Grohè, Matteo, Santoni, Francesca, Morgese, Mariangela, Torniai, Agnese, Savini, Ilaria, Fiordoliva, Stefano, Cascinu
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 01.06.2016
Subjects
Antidiuretic hormone
Cancer
Chronic Disease
Hematology, Oncology and Palliative Medicine
Humans
Hyponatremia
Hyponatremia - etiology
Hyponatremia - physiopathology
Hyponatremia - therapy
Neoplasms - complications
SIADH
Sodium
Vasopressin
Antidiuretic hormone
Hyponatremia
Sodium
SIADH
Vasopressin
Cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Hyponatremia is relevant in cancer patients because it may have a negative impact on outcome, on quality of life and on length of hospitalization. • There are evidences that the inappropriate antidiuretic hormone syndrome (SIADH) is the most common cause of hyponatremia in cancer patients. • An early detection, monitoring and prompt management is needed to improve the patient’s outcome and several options are available. • Several studies have demonstrated the efficacy and good tolerability of Tolvaptan for the treatment of SIADH-related hyponatremia even in cancer patients.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2016.03.010